(+51) 996444221 CONTÁCTENOS

Filmotecas

- Cáncer de mama
- VI International Symposium Of Breast Cancer
Which is the ideal time for using GnRH analogs in EBC HR positive premenopausal women? Por Dr. Matteo Lambertini
- Cáncer de mama
- VI International Symposium Of Breast Cancer
It is still room for chemotherapy in metastatic HR positive, Her2 negative breast cancer? Por Dr. Carlos Castañeda
- Cáncer de mama
- VI International Symposium Of Breast Cancer
Introduction to the Comprehensive genomic profiling in breast cancer. Por Dra Veridiana Cano
- Cáncer de mama
- VI International Symposium Of Breast Cancer
Mechanism of resistance in Her2 +++ and how to reverse it with the new drugs. Por Dra. Sara Tolaney
- Cáncer de mama
- VI International Symposium Of Breast Cancer
The precision Medicine needs to have a better understanding of gene profile for improving trial design for better results lowering or avoiding recurrences instead of use only IHC. Por Dr. Ashley Alarcon
- Cáncer de mama
- VI International Symposium Of Breast Cancer
Updating the mHer2 BC with the new drugs: any new algorithm. Por Dr. Guiseppe Curigliano
- Cáncer de mama
- VI International Symposium Of Breast Cancer
Real World Experience with iCDK4/6 in the Management of RH+HER2- Metastatic Breast Cancer. Por Dr. Fernando Petracci
- Cáncer de mama
- VI International Symposium Of Breast Cancer
Characterization and targeting of minimal residual disease. Por Dr. Daniel Castro
- Cáncer de mama
- VI International Symposium Of Breast Cancer
For locoregional recurrence is enough the use of local treatment or does it depend of type of cancer. Por Dr. Sherko Kuemmel
- Cáncer de mama
- VI International Symposium Of Breast Cancer
What to do with axillary negative management after neoadjuvant treatment? Por Dr. Marcelo Chavez
- Cáncer de mama
- VI International Symposium Of Breast Cancer
Early approach to HER2+ breast cancer. Por Dr. Adrian Nervo
- Cáncer de mama
- VI International Symposium Of Breast Cancer
Basic research and translational research how they impact on the design of phase II and III trials if ideally developing countries have all these technology with own data Does it impact in the economy for treatment cancers? Por Dr. Renzo Alvarez
- Cáncer de mama
- VI International Symposium Of Breast Cancer
How important and necessary is the technology, and to have our own data in each developing country, for treating cancer, how could you measure the impact? Por Dr Osbert Mejia
- Cáncer de mama
- VI International Symposium Of Breast Cancer
What we learn of ADCs are these the future of oncology instead of other treatments combined with chemotherapy? Por Dr. Manuel Philco
- Cáncer de mama
- VI International Symposium Of Breast Cancer
The future of TNBC. Por Dr Jose Zorrilla
- Cáncer de mama
- VI International Symposium Of Breast Cancer
Benefit of immunotherapy in the treatment of triple negative breast cancer: early stages. Por Dr Walter Li Torres